• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    China Targeted Liposomes Drug Delivery Market

    ID: MRFR/Pharma/49798-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    China Targeted Liposomes Drug Delivery Market Research Report By Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, others) and By Application (Fungal Infection Therapy, Cancer Therapy, others)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    China Targeted Liposomes Drug Delivery Market Research Report- Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    China Targeted Liposomes Drug Delivery Market Summary

    The China Targeted Liposomes Drug Delivery market is projected to grow from 200.2 million USD in 2024 to 845 million USD by 2035.

    Key Market Trends & Highlights

    China Targeted Liposomes Drug Delivery Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate of 13.98 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 845 million USD, indicating robust growth potential.
    • In 2024, the market is valued at 200.2 million USD, reflecting a strong foundation for future expansion.
    • Growing adoption of targeted drug delivery systems due to increasing prevalence of chronic diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 200.2 (USD Million)
    2035 Market Size 845 (USD Million)
    CAGR (2025-2035) 13.98%

    Major Players

    Sinopharm Group, Pfizer, Boehringer Ingelheim, Innovent Biologics, Fosun Pharmaceutical, Janssen Pharmaceuticals, Shanghai Pharmaceuticals, Thermo Fisher Scientific, WuXi AppTec, Jiangsu Hengrui Medicine, AstraZeneca, Roche, Zai Lab, CSPC Pharmaceutical Group, Novartis

    China Targeted Liposomes Drug Delivery Market Trends

    The China Targeted Liposomes Drug Delivery Market is experiencing notable trends driven by advancements in pharmaceutical technologies and increased focus on personalized medicine. Key market drivers include the rising prevalence of chronic diseases such as cancer and cardiovascular ailments, prompting a demand for highly effective drug delivery systems. The Chinese government's support in terms of funding and policy encouragement for biopharmaceutical innovations further stimulates the market. 

    Regulatory bodies, such as the National Medical Products Administration, are working to expedite the approval process for new drug delivery technologies, which enhances market growth prospects.The integration of nanotechnology with liposomal formulations to enhance drug efficacy and mitigate adverse effects is one of the opportunities to be investigated in this market. Additionally, the identification of novel drug compounds encapsulated within liposomes, which can be used to address unmet medical requirements, can result from collaborations between pharmaceutical companies and research institutions. 

    The emergence of biotechnology companies that specialise in targeted therapeutics presents a substantial opportunity for market expansion as they develop more specialised drug delivery solutions. In recent years, the utilisation of targeted liposomal delivery systems has become increasingly popular among pharmaceutical developers and researchers in China. 

    Various universities and research centres are also experimenting with innovative methods for drug encapsulation and release, which is evident in the increased investments in research and development activities. The growing trend towards targeted therapies and the emphasis on patient-centered treatment options and the reduction of adverse effects render liposomal drug delivery systems even more pertinent in the evolving healthcare landscape of China.

      

    China Targeted Liposomes Drug Delivery Market Drivers

    Market Segment Insights

    China Targeted Liposomes Drug Delivery Market Segment Insights

    China Targeted Liposomes Drug Delivery Market Segment Insights

    Targeted Liposomes Drug Delivery Market Type Insights

    Targeted Liposomes Drug Delivery Market Type Insights

    The China Targeted Liposomes Drug Delivery Market is characterized by a diverse range of options within its Type segment, which includes Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, and others. Liposomal Doxorubicin is widely recognized for its efficacy in treating various types of cancers, significantly improving patient outcomes through targeted delivery mechanisms that minimize systemic toxicity. This type of liposomal formulation has a prominent presence in the market and plays a crucial role in enhancing the therapeutic index of anti-cancer drugs. 

    Similarly, Liposomal Paclitaxel is essential in cancer therapy, particularly for solid tumors, as it enhances the solubility and stability of the drug while delivering a concentrated effect directly to tumor sites. The importance of such targeted delivery is substantial, as it has the potential to reduce side effects and improve the quality of life for patients undergoing aggressive chemotherapy. 

    On the other hand, Liposomal Amphotericin B is significant in the treatment of serious fungal infections, particularly in immunocompromised patients. Its formulation enhances the drug's safety profile by reducing nephrotoxicity, thereby making it a preferable option for treating infections without severely compromising renal function. 

    The continued advancements in targeted liposomal formulations fuel the growth of the China Targeted Liposomes Drug Delivery Market, driven by the increasing occurrence of cancer and infectious diseases within the region. As the country strives for innovation in drug delivery systems, these liposomal types represent not only effective therapeutic tools but also align with the broader healthcare goals set forth by the Chinese government to enhance patient care and treatment efficacy. 

    Targeted Liposomes Drug Delivery Market Application Insights

    Targeted Liposomes Drug Delivery Market Application Insights

    The China Targeted Liposomes Drug Delivery Market exhibits significant growth potential across various applications, notably in areas such as Fungal Infection Therapy and Cancer Therapy, which are crucial for patient care in the region. The growing prevalence of fungal infections and cancer cases in China underscores the importance of effective drug delivery systems. Fungal Infection Therapy benefits greatly from targeted liposomes as they enhance the bioavailability and efficacy of antifungal agents, which is vital in overcoming resistance issues.

    Similarly, Cancer Therapy leverages targeted liposomes to deliver chemotherapy drugs directly to tumor sites, minimizing systemic toxicity while improving therapeutic outcomes. The market is also witnessing diversification with additional applications that cater to the evolving healthcare landscape, reflecting a robust pipeline of innovative solutions aimed at addressing complex medical challenges. 

    The progressive regulatory environment in China, coupled with increasing investments in Research and Development, is anticipated to further propel the growth of the targeted liposome delivery systems, making them essential components in modern therapeutic regimens.Market trends show a rising interest from pharmaceutical companies in utilizing these advanced delivery mechanisms, resulting in enhanced patient compliance and overall treatment effectiveness.

    Get more detailed insights about China Targeted Liposomes Drug Delivery Market Research Report- Forecast to 2035

    Regional Insights

    Key Players and Competitive Insights

    The China Targeted Liposomes Drug Delivery Market has witnessed substantial growth in recent years, driven by advancements in nanotechnology and increasing demand for effective therapeutic delivery systems. Targeted liposomes serve as an innovative drug delivery mechanism, enhancing the bioavailability and efficacy of therapeutic agents while minimizing adverse effects. 

    The market is characterized by intense competition among key players who are focusing on R&D to develop novel formulations and technology to gain a competitive edge. The strategic initiatives such as collaborations, partnerships, and mergers are prevalent among companies in this space, aiming to optimize their product offerings and expand market penetration in a rapidly evolving landscape. There is a robust focus on regulatory compliance and quality assurance, ensuring that products meet the stringent standards set by Chinese authorities, which plays a crucial role in sustaining competitive advantages.

    Sinopharm Group stands as a leading player in the China Targeted Liposomes Drug Delivery Market, leveraging its strong distribution network and comprehensive expertise in pharmaceuticals. The company's substantial investment in research and development has enabled it to refine its targeted liposome formulations effectively, yielding significant therapeutic advantages. Sinopharm Group's strength lies in its extensive collaboration with academic institutions and healthcare providers to innovate and improve drug delivery methods, which directly addresses the needs of clinicians and patients in China. 

    The company’s strong market presence, coupled with its reputation for quality and reliability, positions it favorably within the competitive landscape. Sinopharm Group’s solid financial backing and commitment to enhancing patient outcomes through effective drug delivery systems further consolidate its position in the market.Pfizer's involvement in the China Targeted Liposomes Drug Delivery Market showcases its strategic commitment to harnessing advanced drug delivery systems to improve patient outcomes. The company has a broad portfolio of products that leverage liposomal technology to deliver medications more effectively. 

    Pfizer's key assets include an established track record of conducting clinical trials in the region, which solidifies its market presence and regulatory compliance. The company's strengths lie in its innovative approach to drug formulation and delivery, ensuring that its liposomal products meet the specific needs of the Chinese population. Pfizer actively pursues mergers and acquisitions to fortify its position within the region, which has led to enhanced capabilities and expanded research initiatives. 

    This strategic focus allows Pfizer to not only maintain relevance in the competitive landscape but also drive growth through new technological advancements and partnerships that prioritize the development of targeted therapeutic solutions.

    Key Companies in the China Targeted Liposomes Drug Delivery Market market include

    Industry Developments

    The China Targeted Liposomes Drug Delivery Market has seen significant advancements in recent months, with a notable emphasis on enhancing drug efficiency and reducing side effects in treatment protocols. In October 2023, Sinopharm Group announced an increase in their investment in Research and Development for liposomal formulations aimed at tackling cancer therapies. 

    Meanwhile, Innovent Biologics received regulatory approval for their targeted liposome-based drug, which is expected to significantly impact patient outcomes in oncology treatments. During September 2023, Pfizer expanded its collaboration with WuXi AppTec to leverage their expertise in liposomal drug technology, aiming to accelerate the development of new therapeutic products. Additionally, AstraZeneca and Boehringer Ingelheim have committed to joint initiatives to explore innovative liposome delivery mechanisms. 

    In the last two years, several mergers and acquisitions occurred; in May 2022, Roche acquired a minority stake in Zai Lab, focusing on targeted drug delivery advancements, while in March 2023, Jiangsu Hengrui Medicine reported a strategic partnership with Thermo Fisher Scientific aimed at bolstering their liposome production capacities. 

    Moreover, the market is projected to grow significantly as numerous players, including Shanghai Pharmaceuticals and CSPC Pharmaceutical Group, enhance their portfolios through innovative liposomal therapies.

    Market Segmentation

    Targeted Liposomes Drug Delivery Market Type Outlook

    • Liposomal Doxorubicin
    • Liposomal Paclitaxel
    • Liposomal Amphotericin B
    • others

    Targeted Liposomes Drug Delivery Market Application Outlook

    • Fungal Infection Therapy
    • Cancer Therapy
    • others

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 186.0(USD Million)
    MARKET SIZE 2024 200.25(USD Million)
    MARKET SIZE 2035 845.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 13.984% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Sinopharm Group, Pfizer, Boehringer Ingelheim, Innovent Biologics, Fosun Pharmaceutical, Janssen Pharmaceuticals, Shanghai Pharmaceuticals, Thermo Fisher Scientific, WuXi AppTec, Jiangsu Hengrui Medicine, AstraZeneca, Roche, Zai Lab, CSPC Pharmaceutical Group, Novartis
    SEGMENTS COVERED Type, Application
    KEY MARKET OPPORTUNITIES Growing cancer therapeutics demand, Advances in personalized medicine, Increasing investment in biotech innovation, Rising prevalence of chronic diseases, Government support for research initiatives
    KEY MARKET DYNAMICS Increasing cancer prevalence, Growing demand for personalized medicine, Advancements in liposome technology, Supportive regulatory framework, Rising investment in R&D
    COUNTRIES COVERED China

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the projected market size of the China Targeted Liposomes Drug Delivery Market in 2024?

    The market size is expected to be valued at 200.25 million USD in 2024.

    What is the expected market size of the China Targeted Liposomes Drug Delivery Market by 2035?

    By 2035, the market is anticipated to reach a value of 845.0 million USD.

    What is the expected Compound Annual Growth Rate (CAGR) for the China Targeted Liposomes Drug Delivery Market from 2025 to 2035?

    The market is expected to grow at a CAGR of 13.984% during the forecast period.

    Which segment of the China Targeted Liposomes Drug Delivery Market is expected to have the largest share in 2024?

    The 'others' segment is anticipated to have a substantial share valued at 80.25 million USD in 2024.

    What will be the market value of Liposomal Doxorubicin in 2035?

    Liposomal Doxorubicin is predicted to reach a market value of 165.0 million USD by 2035.

    How much is the Liposomal Amphotericin B segment expected to be valued at in 2024?

    In 2024, the Liposomal Amphotericin B segment is expected to be valued at 35.0 million USD.

    Who are some of the major players in the China Targeted Liposomes Drug Delivery Market?

    Major players include Sinopharm Group, Pfizer, and Boehringer Ingelheim among others.

    What is the projected market size for Liposomal Paclitaxel in 2035?

    Liposomal Paclitaxel is expected to reach a market size of 188.0 million USD by 2035.

    What is driving the growth of the China Targeted Liposomes Drug Delivery Market?

    The growth is driven by advancements in drug delivery technologies and increasing demand for targeted therapies.

    How will the market be impacted by the current global scenario or conflicts?

    Current global scenarios and conflicts may affect supply chains and market access, potentially influencing market growth.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. China Targeted Liposomes Drug Delivery Market, BY Type (USD Million)
    45. Liposomal Doxorubicin
    46. Liposomal Paclitaxel
    47. Liposomal Amphotericin B
    48. others
    49. China Targeted Liposomes Drug Delivery Market, BY Application (USD Million)
    50. Fungal Infection Therapy
    51. Cancer Therapy
    52. others
    53. Competitive Landscape
    54. Overview
    55. Competitive Analysis
    56. Market share Analysis
    57. Major Growth Strategy in the Targeted Liposomes Drug Delivery Market
    58. Competitive Benchmarking
    59. Leading Players in Terms of Number of Developments in the Targeted Liposomes Drug Delivery Market
    60. Key developments and growth strategies
    61. New Product Launch/Service Deployment
    62. Merger & Acquisitions
    63. Joint Ventures
    64. Major Players Financial Matrix
    65. Sales and Operating Income
    66. Major Players R&D Expenditure. 2023
    67. Company Profiles
    68. Sinopharm Group
    69. Financial Overview
    70. Products Offered
    71. Key Developments
    72. SWOT Analysis
    73. Key Strategies
    74. Pfizer
    75. Financial Overview
    76. Products Offered
    77. Key Developments
    78. SWOT Analysis
    79. Key Strategies
    80. Boehringer Ingelheim
    81. Financial Overview
    82. Products Offered
    83. Key Developments
    84. SWOT Analysis
    85. Key Strategies
    86. Innovent Biologics
    87. Financial Overview
    88. Products Offered
    89. Key Developments
    90. SWOT Analysis
    91. Key Strategies
    92. Fosun Pharmaceutical
    93. Financial Overview
    94. Products Offered
    95. Key Developments
    96. SWOT Analysis
    97. Key Strategies
    98. Janssen Pharmaceuticals
    99. Financial Overview
    100. Products Offered
    101. Key Developments
    102. SWOT Analysis
    103. Key Strategies
    104. Shanghai Pharmaceuticals
    105. Financial Overview
    106. Products Offered
    107. Key Developments
    108. SWOT Analysis
    109. Key Strategies
    110. Thermo Fisher Scientific
    111. Financial Overview
    112. Products Offered
    113. Key Developments
    114. SWOT Analysis
    115. Key Strategies
    116. WuXi AppTec
    117. Financial Overview
    118. Products Offered
    119. Key Developments
    120. SWOT Analysis
    121. Key Strategies
    122. Jiangsu Hengrui Medicine
    123. Financial Overview
    124. Products Offered
    125. Key Developments
    126. SWOT Analysis
    127. Key Strategies
    128. AstraZeneca
    129. Financial Overview
    130. Products Offered
    131. Key Developments
    132. SWOT Analysis
    133. Key Strategies
    134. Roche
    135. Financial Overview
    136. Products Offered
    137. Key Developments
    138. SWOT Analysis
    139. Key Strategies
    140. Zai Lab
    141. Financial Overview
    142. Products Offered
    143. Key Developments
    144. SWOT Analysis
    145. Key Strategies
    146. CSPC Pharmaceutical Group
    147. Financial Overview
    148. Products Offered
    149. Key Developments
    150. SWOT Analysis
    151. Key Strategies
    152. Novartis
    153. Financial Overview
    154. Products Offered
    155. Key Developments
    156. SWOT Analysis
    157. Key Strategies
    158. References
    159. Related Reports
    160. China Targeted Liposomes Drug Delivery Market SIZE ESTIMATES & FORECAST, BY TYPE, 2019-2035 (USD Billions)
    161. China Targeted Liposomes Drug Delivery Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    162. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    163. ACQUISITION/PARTNERSHIP
    164. MARKET SYNOPSIS
    165. CHINA TARGETED LIPOSOMES DRUG DELIVERY MARKET ANALYSIS BY TYPE
    166. CHINA TARGETED LIPOSOMES DRUG DELIVERY MARKET ANALYSIS BY APPLICATION
    167. KEY BUYING CRITERIA OF TARGETED LIPOSOMES DRUG DELIVERY MARKET
    168. RESEARCH PROCESS OF MRFR
    169. DRO ANALYSIS OF TARGETED LIPOSOMES DRUG DELIVERY MARKET
    170. DRIVERS IMPACT ANALYSIS: TARGETED LIPOSOMES DRUG DELIVERY MARKET
    171. RESTRAINTS IMPACT ANALYSIS: TARGETED LIPOSOMES DRUG DELIVERY MARKET
    172. SUPPLY / VALUE CHAIN: TARGETED LIPOSOMES DRUG DELIVERY MARKET
    173. TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY TYPE, 2025 (% SHARE)
    174. TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY TYPE, 2019 TO 2035 (USD Billions)
    175. TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY APPLICATION, 2025 (% SHARE)
    176. TARGETED LIPOSOMES DRUG DELIVERY MARKET, BY APPLICATION, 2019 TO 2035 (USD Billions)
    177. BENCHMARKING OF MAJOR COMPETITORS

    China Targeted Liposomes Drug Delivery Market Segmentation

     

     

     

    • Targeted Liposomes Drug Delivery Market By Type (USD Million, 2019-2035)

      • Liposomal Doxorubicin
      • Liposomal Paclitaxel
      • Liposomal Amphotericin B
      • others

     

    • Targeted Liposomes Drug Delivery Market By Application (USD Million, 2019-2035)

      • Fungal Infection Therapy
      • Cancer Therapy
      • others

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials